ADAlessia Delizia

Alessia Delizia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessia Delizia has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biochemical Basis and Therapeutic Relevance of Cathepsins in Cancer: Recent Advances

    by Mariapia Vietri, Alessia Delizia, Tania Ciaglia, Carla Sardo, Simona Musella, Veronica Di Sarno, Carmine Ostacolo, Ornella Moltedo, Dan Lindholm, Mario Felice Tecce, et al.

    Background/Objectives: Cathepsins, a family of lysosomal proteases essential for cellular proteostasis, have functions that extend beyond canonical degradation and recycling processes. Their dysregulation has been strongly associated with tumorigenesis, where cathepsins promote multiple hallmarks of cancer, including extracellular matrix remodeling, invasion, proliferation, and inflammation. Both intracellular and extracellular cathepsin activities contribute to tumor microenvironment shaping and influence the response to anticancer therapies, particularly chemoresistance. This review aims to summarize current knowledge on the biochemical regulation of cathepsins in cancer and evaluate their potential as therapeutic targets. Methods: A comprehensive literature analysis was conducted, focusing on recent in vitro, in vivo, and translational studies examining cathepsins’ functions, substrate specificity, biochemical pathways, and pharmacological modulations. Special attention was given to research addressing inhibitor development, therapeutic targeting strategies, and challenges associated with selectivity, delivery, and model variability. Results: Evidence indicates that cathepsins exhibit a multifaceted role in cancer. Extracellular cathepsins facilitate matrix degradation and metastatic dissemination, while intracellular cathepsins regulate key signaling networks that promote tumor cell survival, proliferation, autophagy, and inflammatory responses. Furthermore, cathepsins contribute to tumor microenvironment remodelling and modulate sensitivity to chemotherapy, supporting multiple mechanisms of therapy resistance. Although preclinical studies highlight promising therapeutic opportunities, significant limitations persist, including poor inhibitor specificity, challenges in drug delivery, compensatory activation among cathepsin isoforms that may sustain overlapping proteolytic functions, and heterogeneous responses across tumor types. Conclusions: Targeting cathepsins is an emerging strategy in oncology, but effective translation requires a deeper understanding of the complex biochemical networks they regulate. Given their broad and interconnected roles, clarifying these pathways is essential to anticipate global effects and potential toxicities. Future work should therefore define this molecular hub and develop approaches that ensure selective and safe cathepsin modulation.

  • Open Access

    SGLT2 Inhibitors in Alzheimer’s Disease: Biochemical Insights and Therapeutic Potential

    by Pietro Mazzeo, Mariapia Vietri, Nicola Tecce, Alessia Delizia, Valentina Remondelli, Tania Ciaglia, Anna Di Dio, Laura Corletti, Carmine Gerardo Pizzuti, Giacomo Pepe, et al.

    Sodium–glucose cotransporter-2 (SGLT2) inhibitors, initially developed as antidiabetic agents, have recently gained attention for their potential role in modulating processes relevant to Alzheimer’s disease (AD). Preclinical studies suggest that they may influence key mechanisms involved in AD. However, available clinical studies, mainly retrospective and focused on diabetic populations, provide insufficient clarity on whether these effects extend to broader, non-diabetic groups. The heterogeneity of neurodegenerative diseases, which differ in inflammatory and proteotoxic mechanisms, further highlights the need for disease-specific investigations. This review examines mechanistic pathways through which SGLT2 inhibition may influence AD progression and evaluates current clinical evidence, aiming to identify key knowledge gaps and guide future research. This review summarises the latest evidence from the literature, focusing on preclinical experiments, translational studies and early clinical observations. The search focused on pathways related to microglial and astrocytic activation, oxidative stress, metabolic remodeling, neuronal survival, and amyloid and tau dynamics. Accumulating data indicate that SGLT2 inhibitors exert multifaceted actions relevant to AD pathology, including reduced neuroinflammation and oxidative stress, improved mitochondrial and insulin signaling, as well as decreased amyloid deposition and tau hyperphosphorylation. Additionally, SGLT2 inhibition may improve cerebrovascular perfusion and blood–brain barrier stability, potentially supporting cognitive function. Nonetheless, major challenges remain, including variable blood–brain barrier permeability and heterogeneous experimental responses. SGLT2 inhibitors represent a promising pleiotropic class of compounds with potential disease-modifying effects in AD. Their capacity to target metabolic, inflammatory, and proteotoxic pathways makes them attractive candidates for neurodegenerative therapy. Further studies are required to clarify biochemical pathways and validate clinical efficacy.